Michael Medinger
Overview
Explore the profile of Michael Medinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1044
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meier-Lienhard R, Suter C, Pabst T, Hitz F, Passweg J, Spertini O, et al.
Swiss Med Wkly
. 2025 Jan;
155():3885.
PMID: 39877935
Introduction: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease, with unique diagnostic challenges and often dismal outcome. There are no widely accepted treatment guidelines available. Lymphoma-like regimens...
2.
Goldin I, Medinger M, Passweg J, Halbeisen D
Case Rep Oncol
. 2024 Oct;
17(1):1103-1108.
PMID: 39474539
Introduction: All-trans retinoic acid (ATRA) in combination with arsenic trioxide (ATO) is standard therapy for low-to-intermediate risk acute promyelocytic leukemia (APL). Isotretinoin, an agent used for acne vulgaris, is similar...
3.
Bader M, Kubetzko S, Schafer B, Arranto C, Drexler B, Halter J, et al.
Ann Hematol
. 2024 Aug;
103(11):4831-4833.
PMID: 39167183
No abstract available.
4.
Janscak M, Stelmes A, van den Berg J, Heim D, Halter J, Drexler B, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1525-1533.
PMID: 39138337
The hematopoietic comorbidity risk index (HCT-CI) is a pre-transplant risk assessment tool used to qualify comorbidities to predict non-relapse mortality (NRM) of patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT)....
5.
Heim D, Baldomero H, Medinger M, Masouridi-Levrat S, Schanz U, Nair G, et al.
Swiss Med Wkly
. 2024 May;
154:3754.
PMID: 38749067
Aim: Until the year 2000, allogeneic haematopoietic cell transplantation (HCT) was the standard treatment for young and fit chronic myeloid leukaemia (CML) patients. CML was the main indication for allogeneic...
6.
Konig D, Sandholzer M, Uzun S, Zingg A, Ritschard R, Thut H, et al.
Cancer Immunol Res
. 2024 Apr;
12(7):814-821.
PMID: 38631025
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is effective in patients with melanoma, although long-term responses seem restricted in patients who have complete remissions. Many patients develop secondary resistance...
7.
Seydoux C, Satyanarayana Uppugunduri C, Medinger M, Nava T, Halter J, Heim D, et al.
Bone Marrow Transplant
. 2023 Dec;
59(2):294.
PMID: 38129515
No abstract available.
8.
Ben Hassine K, Seydoux C, Khier S, Daali Y, Medinger M, Halter J, et al.
Transplant Cell Ther
. 2023 Dec;
30(3):332.e1-332.e15.
PMID: 38081414
Therapeutic drug monitoring (TDM) of busulfan (Bu) is well-established in pediatric hematopoietic stem cell transplantation (HSCT), but its use in adults is limited due to a lack of clear recommendations...
9.
Ragozzino S, Mueller N, Neofytos D, Passweg J, Muller A, Medinger M, et al.
Bone Marrow Transplant
. 2023 Nov;
59(2):278-281.
PMID: 38036657
No abstract available.
10.
Jungius S, Adam F, Grosheintz K, Medinger M, Buser A, Passweg J, et al.
Front Oncol
. 2023 Aug;
13:1205387.
PMID: 37637037
Introduction: Myelofibrosis (MF) is a rare hematopoietic stem cell disorder progressing to bone marrow (BM) failure or blast phase. Allogeneic hematopoietic cell transplantation (HCT) represents a potentially curative therapy for...